Anthropic, the artificial intelligence (AI) firm behind Claude, has just bought a small biotech startup called Coefficient Bio for about $400 million. The company aims to expand its AI services into specific fields, including medicine and science. After the acquisition, Coefficient Bio’s team will work with Anthropic’s healthcare group, providing expert skills.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Anthropic Expands into Healthcare with AI Tools
Anthropic has taken over Coefficient Bio to improve its AI services in healthcare. The biotech startup built tools that help AI understand and work on complex science tasks. These tasks include drug discovery, research planning, and complying with medical regulations. The new acquisition will help medical professionals in the healthcare system work faster and make better choices.
This purchase also shows that Anthropic is not only focused on building general tools and making profits, but also on building tools for specific industries like medicine, where AI can have a meaningful impact.
Anthropic Improves Claude for Medical Use
Anthropic has been developing its AI assistant, Claude, to help scientists, doctors, and researchers in the medical field. The AI tool can now write medical documents and support research after some improvements to its features.
Anthropic is also collaborating with major healthcare companies such as Sanofi (SNY) and Novo Nordisk (NVO) to improve its services within the healthcare system. The private company is also ensuring its AI follows medical standards of operation to provide the right information to users and medical officers. By integrating Coefficient Bio’s technology, the firm hopes to create better, safer tools that will help advance the healthcare system.
Which Biotech Stocks Can I Buy Now?
Wall Street analysts tracked by TipRanks are currently rating Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) as “Strong Buy”, while Sanofi (SNY) is rated “Moderate Buy”. Investors tracking biotech sectors often compare analyst ratings, price targets, and drug pipeline strength to evaluate these stocks. For more information on these Biotech stocks’ performance, ratings, and price targets, visit the TipRanks Stocks Comparison Center.
